I had to undergo surgery a few months ago and the recovery wiped out most of my time, so it's taken me much longer than expected to write the next article in this series on Novavax (NASDAQ:NVAX). I'm feeling far better now, so with Novavax's earnings call having just taken place Monday, let's dive in.
This article will primarily focus on an evaluation of Novavax's multi-arm trial for its elderly RSV vaccine candidate and how it impacts the probability of the next phase 3 for it succeeding. It will also describe what the company said about the phase 2 on Monday's conference call.
